In a recent study by Ghiani et al., the potential of an AAZTA-chelated PSMA inhibitor (B28110) radiolabelled with 44Sc ([44Sc]Sc-B28110) was confirmed for the PET imaging of prostate cancer [94]. Here, FOLH1 is linked to prostate cancer.